The study included more than 500 patients with recurrent ovarian cancer and found that both women with and without a BRCA gene mutation — which helps suppress tumors and make women more treatable — responded positively to the drug.
In patients with a BRCA mutation, progression-free survival for those treated with niraparib was 21 months, compared to 5.5 months for those on a placebo. Patients without the BRCA mutation had a progression-free survival of 9.3 months compared to 3.9 months for those on the placebo.
Researchers said data from the study increases the likelihood that niraparib will be used as a first line treatment for women with ovarian cancer and BRCA-related breast cancer.
Stocks of the Waltham, Mass.-based drugmaker more than doubled to $77 a share in response to news of the trial’s results.
More articles on the drug market:
Viewpoint: 4 reasons the FDA should ditch the pass/fail drug approval process
Pfizer to build $350M biotech center in China
Novartis partners with Xencor to develop bispecific antibodies
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.